Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + penpulimab + capecitabine
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib + penpulimab + capecitabine is a combination regimen under investigation for the treatment of various advanced or recurrent cancers, including nasopharyngeal carcinoma. Anlotinib is a small molecule oral multi-targeted tyrosine kinase inhibitor that blocks tumor angiogenesis and growth by inhibiting VEGFR1/2/3, FGFR1–4, and PDGFRα/β. Penpulimab is a humanized IgG1 monoclonal antibody targeting programmed cell death protein 1 (PD‑1), designed to block immune checkpoint signaling and enhance anti-tumor immunity; it features modifications to eliminate Fc receptor-mediated effector functions. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which inhibits DNA synthesis in rapidly dividing cells. This combination aims to leverage antiangiogenic, immunotherapeutic, and cytotoxic mechanisms for synergistic anti-tumor effects[1][2][3][6].
- Brand names
- Elunate
- Other names
- anlotinib hydrochlorideN-(4-{(2-(dimethylamino)ethyl)[(1R)-1-methylpyrrolidinyl]amino}phenyl)-4-(1H-indazol-6-yloxy)pyrimidin-2-amide
02
Targets
TS (Thymidylate synthase)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on anlotinib + penpulimab + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + penpulimab + capecitabine.